Inactive Instrument
Checkmate Pharmaceuticals, Inc. Share Price
Stocks
CMPI
US1628181083
Biotechnology & Medical Research
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 11/12/2018 | |
Robert Landry
DFI | Director of Finance/CFO | 62 | 30/05/2022 |
James Wooldridge
CTO | Chief Tech/Sci/R&D Officer | 60 | 30/09/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Nouhad Husseini
BRD | Director/Board Member | - | 30/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/22 | Issuer sale | Director | 36,778 | 0.1700% | ||
| 31/05/22 | Issuer sale | Chief Financial Officer | 278,480 | 1.2874% | ||
| 31/05/22 | Issuer sale | Chief Executive Officer | 279,437 | 1.2919% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +0.38% | - | - | 231M | |
| +0.41% | -2.07% | +41.26% | +95.40% | 69.02B | |
| -1.38% | +0.49% | +42.48% | +89.43% | 66.32B | |
| +0.04% | +4.36% | -11.72% | +459.54% | 27.66B | |
| -0.90% | -7.65% | +2.45% | -15.50% | 25.84B | |
| -3.00% | -2.90% | +39.40% | +9.41% | 26.54B | |
| -0.59% | +1.44% | +25.33% | -17.87% | 20.4B | |
| +3.45% | -13.46% | +222.69% | +389.50% | 17.63B | |
| -1.49% | -4.88% | -0.41% | +530.26% | 15.15B | |
| +1.03% | +7.00% | +59.98% | +160.03% | 14.65B | |
| Average | -0.24% | -1.37% | +46.83% | +188.91% | 31.47B | |
| Weighted average by Cap. | -0.44% | -0.83% | +41.54% | +148.15% |
Employees
31
